

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



20 September 2021

UBI extends clinical development trials for Tn Antigen cancer biosensor

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce that it has entered into agreements with Victorian Cancer Biobank (part of Cancer Council Victoria) and the internationally recognised Centre for Cooperative Research in Bioscience, CIC bioGUNE – BRTA (together with its clinical partner Basurto University Hospital, Spain) to commence clinical studies for its cancer biosensor, Tn Antigen (Tn). The studies will be conducted in Melbourne and Bilbao, Spain.

The trials will include 280 patients and be conducted under Good Clinical Practice.

- One hundred and sixty (160) prostate patient samples will be studied at CIC Biogune - Basurto University Hospital.
- One hundred and twenty (120) cancer patient samples from Victorian Cancer Biobank will be studied in Melbourne (40 breast, 40 prostate, 40 colorectal).
- Each patient blood sample will be used to determine the clinically relevant range of Tn concentrations, confirm the role of Tn in multiple cancer types and validate the performance of UBI's handheld point-of-care device cancer biosensor.

UBI's objective is for the handheld Tn biosensor to accurately measure a patient's cancer status (monitoring of remission and reoccurrence) in easier, cheaper and more frequent tests. Ultimately the Tn biosensor has the potential to be used for the early cancer diagnosis and disease staging.

John Sharman, CEO of UBI said; "Following on from our agreement with Peter Mac, these two new agreements will facilitate the continued development and finalisation of UBI's handheld point-of-care cancer biosensor, which is very exciting for the company."

Prof Arkaitz Carracedo of CIC bioGUNE (Spain) said; "We are excited to be involved in the development of the Tn cancer biosensor. CIC bioGUNE is an internationally recognized center with a strong program on prostate cancer research, in tandem with Basurto University Hospital as clinical partner, led by Dr. Miguel Unda. We hope that our participation in these studies will lead to the success of this biosensor that will improve the management and cure of this disease with technological implementations that are at close reach for the general population."

End

Enquiries:

John Sharman
Chief Executive Officer
+61 (0) 414 440 680

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.

About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. Our wine testing platform Sentia is UBI's newest product which is being launched globally. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

About CIC bioGUNE

CIC bioGUNE is member of the Basque Research and Technology Alliance (BRTA), is a key research center within the national and international scientific landscape and has emerged as a knowledge source in the area of health science. The cutting-edge scientific activity of CIC bioGUNE's researchers explores the interface between Chemistry, Structural, Molecular and Cell Biology, with the aim of developing a more Precise Medicine for the future.

About Victorian Cancer Biobank

The Victorian Cancer Biobank (VCB) is an open-access, not-for-profit tissue resource established by the Victorian Government, Australia and our partnered health care providers to facilitate translational research. The VCB provides cancer researchers with a diverse selection of high-quality biospecimens and derivatives, comprehensively annotated with de-identified clinical outcome data.

About Basurto University Hospital y/o Biobanco Vasco

The Basurto University Hospital is a public health centre situated in the Basurto neighbourhood of Bilbao, Spain. It is dependent on the Basque Health Service and is currently a university hospital. Along with University Hospital of Cruces, Hospital de Basurto is also one of the hospitals of Basque Health Service, reputedly offers and treats the patients of the city of Baracaldo, Uribe, Bilbao and Encartaciones. It is one of the busiest health care centres in the Basque country in Spain.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.